Literature DB >> 19015250

Immunodominance in mouse and human CD4+ T-cell responses specific for the Bordetella pertussis virulence factor P.69 pertactin.

Rachel M Stenger1, Martien C M Poelen, Ed E Moret, Betsy Kuipers, Sven C M Bruijns, Peter Hoogerhout, Marcel Hijnen, Audrey J King, Frits R Mooi, Claire J P Boog, Cécile A C M van Els.   

Abstract

P.69 pertactin (P.69 Prn), an adhesion molecule from the causative agent of pertussis, Bordetella pertussis, is present in cellular and most acellular vaccines that are currently used worldwide. Although both humoral immunity and cellular immunity directed against P.69 Prn have been implicated in protective immune mechanisms, the identities of CD4(+) T-cell epitopes on the P.69 Prn protein remain unknown. Here, a single I-A(d)-restricted B. pertussis conserved CD4(+) T-cell epitope at the N terminus of P.69 Prn was identified by using a BALB/c T-cell hybridoma. The epitope appeared immunodominant among four other minor strain-conserved P.69 Prn epitopes recognized after vaccination and B. pertussis infection, and it was capable of evoking a Th1/Th17-type cytokine response. B. pertussis P.69 Prn immune splenocytes did not cross-react with natural variants of the epitope as present in Bordetella parapertussis and Bordetella bronchiseptica. Finally, it was found that the immunodominant P.69 Prn epitope is broadly recognized in the human population by CD4(+) T cells in an HLA-DQ-restricted manner. During B. pertussis infection, the epitope was associated with a Th1-type CD4(+) T-cell response. Hence, this novel P.69 Prn epitope is involved in CD4(+) T-cell immunity after B. pertussis vaccination and infection in mice and, more importantly, in humans. Thus, it may provide a useful tool for the evaluation of the type, magnitude, and maintenance of B. pertussis-specific CD4(+) T-cell mechanisms in preclinical and clinical vaccine studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19015250      PMCID: PMC2632029          DOI: 10.1128/IAI.00769-08

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  51 in total

1.  Modulation of the infant immune responses by the first pertussis vaccine administrations.

Authors:  F Mascart; M Hainaut; A Peltier; V Verscheure; J Levy; C Locht
Journal:  Vaccine       Date:  2006-11-03       Impact factor: 3.641

2.  Polymorphisms of the fimbria fim3 gene of Bordetella pertussis strains isolated in Canada.

Authors:  Raymond S W Tsang; Allan K H Lau; Michelle L Sill; Scott A Halperin; Paul Van Caeseele; Frances Jamieson; Irene E Martin
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

Review 3.  Are vaccination programs and isolate polymorphism linked to pertussis re-emergence?

Authors:  Fabrice Godfroid; Philippe Denoël; Jan Poolman
Journal:  Expert Rev Vaccines       Date:  2005-10       Impact factor: 5.217

4.  The Bordetella pertussis virulence factor P.69 pertactin retains its immunological properties after overproduction in Escherichia coli.

Authors:  Marcel Hijnen; Pieter G M van Gageldonk; Guy A M Berbers; Tiest van Woerkom; Frits R Mooi
Journal:  Protein Expr Purif       Date:  2005-05       Impact factor: 1.650

5.  Natural peptides selected by diabetogenic DQ8 and murine I-A(g7) molecules show common sequence specificity.

Authors:  Anish Suri; James J Walters; Michael L Gross; Emil R Unanue
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

6.  Influence of CR3 (CD11b/CD18) expression on phagocytosis of Bordetella pertussis by human neutrophils.

Authors:  Paula S Mobberley-Schuman; Alison A Weiss
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

7.  TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells.

Authors:  Sarah C Higgins; Andrew G Jarnicki; Ed C Lavelle; Kingston H G Mills
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

Review 8.  Factors contributing to pertussis resurgence.

Authors:  Qiushui He; Jussi Mertsola
Journal:  Future Microbiol       Date:  2008-06       Impact factor: 3.165

Review 9.  Recent developments in pertussis.

Authors:  Natasha S Crowcroft; Richard G Pebody
Journal:  Lancet       Date:  2006-06-10       Impact factor: 79.321

10.  Comparison of acellular pertussis vaccines-induced immunity against infection due to Bordetella pertussis variant isolates in a mouse model.

Authors:  Philippe Denoël; Fabrice Godfroid; Nicole Guiso; Hans Hallander; Jan Poolman
Journal:  Vaccine       Date:  2005-07-11       Impact factor: 3.641

View more
  10 in total

1.  Molecular epidemiology of the pertussis epidemic in Washington State in 2012.

Authors:  Katherine E Bowden; Margaret M Williams; Pamela K Cassiday; Andrea Milton; Lucia Pawloski; Marsenia Harrison; Stacey W Martin; Sarah Meyer; Xuan Qin; Chas DeBolt; Azadeh Tasslimi; Nusrat Syed; Ronald Sorrell; Mike Tran; Brian Hiatt; Maria Lucia Tondella
Journal:  J Clin Microbiol       Date:  2014-07-16       Impact factor: 5.948

2.  Bordetella pertussis proteins dominating the major histocompatibility complex class II-presented epitope repertoire in human monocyte-derived dendritic cells.

Authors:  Rachel M Stenger; Hugo D Meiring; Betsy Kuipers; Martien Poelen; Jacqueline A M van Gaans-van den Brink; Claire J P Boog; Ad P J M de Jong; Cécile A C M van Els
Journal:  Clin Vaccine Immunol       Date:  2014-03-05

3.  Plasmacytoid dendritic cell-derived IFNα modulates Th17 differentiation during early Bordetella pertussis infection in mice.

Authors:  V Wu; A A Smith; H You; T A Nguyen; R Ferguson; M Taylor; J E Park; P Llontop; K R Youngman; T Abramson
Journal:  Mucosal Immunol       Date:  2015-10-14       Impact factor: 7.313

4.  Molecular and cellular signatures underlying superior immunity against Bordetella pertussis upon pulmonary vaccination.

Authors:  R Hm Raeven; J Brummelman; J L A Pennings; L van der Maas; K Helm; W Tilstra; A van der Ark; A Sloots; P van der Ley; W van Eden; W Jiskoot; E van Riet; C Acm van Els; G Fa Kersten; W Gh Han; B Metz
Journal:  Mucosal Immunol       Date:  2017-09-20       Impact factor: 7.313

5.  Pertactin is required for Bordetella species to resist neutrophil-mediated clearance.

Authors:  Carol S Inatsuka; Qian Xu; Ivan Vujkovic-Cvijin; Sandy Wong; Scott Stibitz; Jeff F Miller; Peggy A Cotter
Journal:  Infect Immun       Date:  2010-04-26       Impact factor: 3.441

6.  Fast, antigen-saving multiplex immunoassay to determine levels and avidity of mouse serum antibodies to pertussis, diphtheria, and tetanus antigens.

Authors:  Rachel M Stenger; Mieke Smits; Betsy Kuipers; Sabine F M Kessen; Claire J P Boog; Cécile A C M van Els
Journal:  Clin Vaccine Immunol       Date:  2011-02-16

7.  Adhesion, invasion, and agglutination mediated by two trimeric autotransporters in the human uropathogen Proteus mirabilis.

Authors:  Praveen Alamuri; Martin Löwer; Jan A Hiss; Stephanie D Himpsl; Gisbert Schneider; Harry L T Mobley
Journal:  Infect Immun       Date:  2010-08-30       Impact factor: 3.441

8.  Loss of multi-epitope specificity in memory CD4(+) T cell responses to B. pertussis with age.

Authors:  Wanda G H Han; Inonge van Twillert; Martien C M Poelen; Kina Helm; Jan van de Kassteele; Theo J M Verheij; Florens G A Versteegh; Claire J P Boog; Cécile A C M van Els
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

9.  Broad-Based CD4+ T Cell Responses to Influenza A Virus in a Healthy Individual Who Lacks Typical Immunodominance Hierarchy.

Authors:  Li Chen; Anjaleena Anthony; Sara Oveissi; Miaojuan Huang; Damien Zanker; Kun Xiao; Chao Wu; Quanming Zou; Weisan Chen
Journal:  Front Immunol       Date:  2017-04-03       Impact factor: 7.561

10.  Genome-wide association study identifies SNPs in the MHC class II loci that are associated with self-reported history of whooping cough.

Authors:  George McMahon; Susan M Ring; George Davey-Smith; Nicholas J Timpson
Journal:  Hum Mol Genet       Date:  2015-07-30       Impact factor: 6.150

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.